Study of Clinical Efficacy and Safety of Tosedostat in MDS

Summary

Study WCMC IST-CTI-MDS evaluates the safety and tolerability of tosedostat in adult patients with pathologically confirmed MDS (\< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification after failure of hypomethylating agent-based therapy.

Timeline

Start

2015-03-20

Primary completion

2017-10-25

Completion

2017-10-25

Publications

• Lee S, Desai P, Edirisinghe B, Pianello S, Curcio T, Samuel M, Ritchie EK, Roboz GJ. Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Leuk Lymphoma. 2021 Feb;62(2):498-500. doi: 10.1080/10428194.2020.1832674. Epub 2020 Oct 10. No abstract available.

Drugs

Indications